Sanford C. Bernstein Reiterates “€37.50” Price Target for Fresenius SE & Co KGaA (FRA:FRE)

Sanford C. Bernstein set a €37.50 ($43.60) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on FRE. Goldman Sachs Group set a €53.00 ($61.63) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Thursday, February 20th. Warburg Research set a €63.00 ($73.26) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Thursday, February 20th. Morgan Stanley set a €51.00 ($59.30) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, March 2nd. Barclays reiterated a neutral rating on shares of Fresenius SE & Co KGaA in a research report on Tuesday, March 3rd. Finally, Berenberg Bank set a €72.10 ($83.84) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, February 24th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Fresenius SE & Co KGaA currently has an average rating of Buy and a consensus price target of €54.83 ($63.75).

Fresenius SE & Co KGaA stock opened at €34.47 ($40.08) on Tuesday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02). The business’s 50-day moving average price is €41.16 and its two-hundred day moving average price is €45.61.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: What are the most popular ETFs

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.